Business
Absci is a clinical-stage biopharmaceutical company using an AI-native approach to design differentiated antibody therapeutics.
Absci advanced an AI-native antibody platform, but revenue disappeared and cash burn widened.
The read at a glance✓ Audited against SEC data
- Business mix — AI-native antibody therapeutics platformNote
- Revenue — FY2025 revenue absent after $4.5M in FY2024Watch
- Profitability — Net loss widened to $115.2MWatch
- Cash burn — Free cash flow was -$94.0MWatch
- Balance sheet — Equity +5.8% to $189.4MOK
- Insiders — 6 buys / 2 sells; $1.0M boughtOK
- Accounting — FY2024 Altman-Z distress; EQ greyWatch
Leadership changes
From Absci Corp's own filings, the day they're filed.
- Andreas Busch · Chief Innovation Officer · departureeff. 2026-03-31
- Mary Szela · directors · appointmenteff. 2025-07-07
- Amrit Nagpal · Directors · departureeff. 2025-04-25
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-06-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Absci Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.